Ranbaxy Laboratories’ arm launches Absorica Capsules in US

26 Nov 2012 Evaluate

Ranbaxy Laboratories’ (RLL) wholly-owned subsidiary - Ranbaxy Laboratories, Inc. (RLI) has launched Absorica (Isotretinoin) capsules, a product that is licensed from Mississauga, Ontario-based Cipher Pharmaceuticals Inc of Mississauage, Ontario. Absorica is indicated for the treatment of severe recalcitrant nodular acne in patients 12 years of age and older.

Due to its high lipophilicity, oral absorption of isotretinoin is enhanced when given with a high-fat meal. However, Absorica, which is formulated using patented Lidose technology, can be given without regards to meals. The fasted AUCo-t of Absorica is around 83 percent greater than that of Accutane, while both products are bio-equivalent under fed conditions. Absorica is, therefore, not interchangeable and not substitutable with generic products of Accutane. Absorica, NDA, was approved based on a large pivotal clinical trial enrolling 925 patients.

Ranbaxy Laboratories is India's largest pharmaceutical company. The company has global presence in 49 countries and is ranked amongst top ten global generics companies. Ranbaxy has world-class manufacturing facilities in 11 countries namely Brazil, China, Ireland, India, Japan, Malaysia, Nigeria, Romania, South Africa, USA and Vietnam.

Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×